NIAGEN BIOSCIENCE INC (NAGE) Stock News

USA - Nasdaq - NASDAQ:NAGE - US1710774076 - Common Stock

6.77 USD

-0.12 (-1.74%)

Last: 11/28/2025, 7:49:47 PM

6.8 USD

+0.03 (+0.44%)

After Hours: 11/28/2025, 7:49:47 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NAGE Latest News, Press Relases and Analysis

All

Press Releases

17 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

17 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

26 days ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

24 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces $10 Million Share Repurchase Program

25 days ago - By: Zacks Investment Research - Mentions: FENC

Niagen Bioscience (NAGE) Surpasses Q3 Earnings and Revenue Estimates

25 days ago - By: Niagen Bioscience, Inc

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

4 months ago - By: Benzinga

Breaking Down Niagen Bioscience: 4 Analysts Share Their Views

a month ago - By: Zacks Investment Research - Mentions: RXRX

Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline

a month ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

2 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

2 months ago - By: Niagen Bioscience, Inc

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

4 months ago - By: Zacks Investment Research - Mentions: CRVO

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

4 months ago - By: The Motley Fool

Niagen NAGE Q2 2025 Earnings Call Transcript

4 months ago - By: Niagen Bioscience, Inc.

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference

4 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

5 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Participate in the BIO 2025 International Convention

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

6 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference

7 months ago - By: Zacks Investment Research - Mentions: NVAX

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates

7 months ago - By: Niagen Bioscience, Inc

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook